1.44
0.04 (3.23%)
| Penutupan Terdahulu | 1.40 |
| Buka | 1.40 |
| Jumlah Dagangan | 1,488,667 |
| Purata Dagangan (3B) | 1,301,492 |
| Modal Pasaran | 574,822,912 |
| Harga / Jualan (P/S) | 338.25 |
| Harga / Buku (P/B) | 97.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Nov 2026 |
| Margin Operasi (TTM) | -17,994.78% |
| EPS Cair (TTM) | -0.590 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.91% |
| Nisbah Semasa (MRQ) | 10.96 |
| Aliran Tunai Operasi (OCF TTM) | -121.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -114.20 M |
| Pulangan Atas Aset (ROA TTM) | -28.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ProKidney Corp. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -1.50 |
|
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 30.05% |
| % Dimiliki oleh Institusi | 42.03% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Artia Global Partners Lp | 30 Jun 2026 | 1,806,939 |
| Brown University | 30 Jun 2026 | 1,000,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |